Rate ratios (RR) for first adverse event according to System Organ Class by treatment group in a randomized double-blind clinical trial of T. suis and placebo, Denmark, 2008.

Indicated below, events recorded in the T. suis group (by subjects, n = x; doctors/nurses, n = xx) and placebo group (by subjects, n = y; doctors/nurses, n = yy) including multiple types in a subject:*Eczema (x = 3, xx = 3, y = 1), skin irritation (x = 3, xx = 3, yy = 1), impetigo (x = 1, xx = 1), rash papular (x = 1, xx = 1), rash (x = 1), sun eczema (x = 1, xx = 1), urticaria (x = 1, xx = 1, y = 1, yy = 1), acne (yy = 1).†Arthralgia (x = 1, xx = 2), myalgia (x = 1, xx = 1, yy = 1), pain in extremity (x = 1, xx = 1), back pain (x = 2, xx = 3, yy = 3), rib fracture (x = 1, xx = 1), wrist fracture (x = 1, xx = 1), musculoskeletal discomfort (x = 1, y = 1, yy = 1), abscess limb (y = 1).‡Discomfort (x = 1, xx = 1, y = 1, yy = 1), fatigue (x = 2, xx = 2, y = 7, yy = 5), feeling of body temperature change (x = 2, xx = 2, y = 7, yy = 7), hunger/stomach acid (y = 1, yy = 1), application site reaction (y = 1, yy = 1, unrelated to T. suis treatment), alcoholic hangover (y = 1), skin tenderness (yy = 1).††Enterobiasis (possible pinworm, xx = 1), herpes zoster (xx = 1), skin infection (yy = 1), ear infection (y = 0), influenza (x = 3, xx = 2, y = 1, yy = 1), chlamydial infection (xx = 1), pneumonia (y = 1,yy = 1), pneumonia viral (yy = 1), varicella (x = 1, xx = 1), and sweating fever (x = 1, xx = 1).‡‡RR could not be calculated because of zero cases in ether or both treatment groups.